All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

One Surgeon’s Spirit and Brilliance Lift a Whole Community

January 3rd 2025

A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology workforce.

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC

January 2nd 2025

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

Generic Platinum Chemotherapy Shortages Did Not Increase Deaths

January 2nd 2025

A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage of generic platinum chemotherapy drugs.

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

January 2nd 2025

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC

January 2nd 2025

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

January 2nd 2025

A NDA has been submitted to the FDA seeking the approval of dordaviprone for recurrent H3K27M-mutant diffuse glioma.

FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

January 2nd 2025

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

A “Rock Star” in Patient-Reported Outcomes, Is Listening

January 2nd 2025

Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.

Epcoritamab Is Associated With Higher Travel Burden/Costs in R/R DLBCL and Follicular Lymphoma

January 2nd 2025

Zachary Frosch, MD, MSHP, discusses the investigation of travel burden/costs related to bispecific antibodies in diffuse large B-cell lymphoma or follicular lymphoma.

A Miracle Maker in Pediatric Hematologic Cancers

January 2nd 2025

A love of collaborating with colleagues from around the globe and a fiery passion to help children diagnosed with cancer led Ching-Hon Pui, MD, to dramatically improve outcomes in pediatric oncology.

A Chance to Choose Your Own Oncology Fellows Content Adventure

January 1st 2025

Participate in the following brief inventory of relevant topics to let us know what topics you want to see explored by Oncology Fellows.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

December 31st 2024

After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and testing checkpoint inhibitors across this malignancy, among several other achievements.

OncLive’s December Roundup of Key FDA Approvals in Oncology

December 30th 2024

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

How a Never-Wavering Enthusiasm Changed Lung Cancer Care for the Better

December 30th 2024

As a female leader in a competitive oncology field, Solange Peters, MD, PhD, pushed through the barriers— climbed over them—and completely transformed lung cancer care with her collaborative spirit.

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

December 30th 2024

Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.

Working on the Frontlines of a Revolution in Multiple Myeloma Care

December 30th 2024

A Mayo Clinic “lifer” who did not consider medicine as a career path until his later teenage years grew into a powerhouse who touched nearly every aspect of the multiple myeloma field, and he continues to push the boundaries of what is possible.

Transparency and Consolidation Issues Hamper 340B Program in Cancer Care

December 30th 2024

Since it's implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and other diseases expanded access to affordable medications by selling drugs at discounted prices to eligible centers.

Paying It Forward: The Importance of Mentorship in a Medical Career

December 29th 2024

Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and a way to pass the torch forward in cancer care.

Preparation is Key to Tackle the Transition from Fellow to Attending Physician

December 29th 2024

A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.